InvAscent India Life Sciences Fund IV
InvAscent India Life Sciences Fund IV is a healthcare-focused growth-equity vehicle managed by Invascent. IFC identifies a US$325 million combined target with the domestic fund, a US$10–50 million average company ticket and five Fund IV investees; InvAscent’s own releases add direct vehicle attribution for Apex Hospitals and SRV Hospitals.
At a glance
- Founded
- 2024
- Footprint
- Hyderabad
- Stage
- Healthcare and life-sciences growth equity
Research profile
Read the manager in sequence.
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
InvAscent India Life Sciences Fund IV uses a healthcare and life-sciences growth equity approach across Pharma, healthcare delivery, medtech, animal health.
Current evidence
InvAscent announced on 30 September 2025 that ILSF IV invested INR 230 crore in Apex Hospitals. Earlier ILSF IV announcements covered SRV Hospitals in April 2025, Geri Care in January 2025, Maiva Pharma in May 2024 and ABI Health Technologies in December 2023.
Strategy
Healthcare and life-sciences growth equity
Sector focus
Pharma, healthcare delivery, medtech, animal health
Current signal
InvAscent announced on 30 September 2025 that ILSF IV invested INR 230 crore in Apex Hospitals. Earlier ILSF IV announcements covered SRV Hospitals in April 2025, Geri Care in January 2025, Maiva Pharma in May 2024 and ABI Health Technologies in December 2023.
Next step
Need this manager reviewed against your mandate?
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.